Titus Ball Sells 132 Shares of BeOne Medicines (NASDAQ:ONC) Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) insider Titus Ball sold 132 shares of the business’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $355.86, for a total transaction of $46,973.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

BeOne Medicines Stock Down 1.2%

BeOne Medicines stock opened at $358.26 on Friday. The firm has a 50 day moving average price of $333.94 and a 200-day moving average price of $311.69. The company has a quick ratio of 3.06, a current ratio of 3.40 and a debt-to-equity ratio of 0.17. BeOne Medicines Ltd. – Sponsored ADR has a twelve month low of $253.95 and a twelve month high of $385.22. The company has a market capitalization of $39.33 billion, a P/E ratio of 63.07 and a beta of 0.51.

BeOne Medicines (NASDAQ:ONC) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $2.05 EPS for the quarter, topping analysts’ consensus estimates of $1.40 by $0.65. BeOne Medicines had a net margin of 10.70% and a return on equity of 14.23%. The company had revenue of $1.71 billion for the quarter, compared to analysts’ expectations of $1.66 billion. As a group, equities analysts predict that BeOne Medicines Ltd. – Sponsored ADR will post 8.81 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have recently commented on ONC shares. TD Cowen upped their price target on BeOne Medicines from $424.00 to $454.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of BeOne Medicines in a report on Friday, July 17th. Citigroup restated an “outperform” rating on shares of BeOne Medicines in a research note on Thursday, August 6th. Citizens Jmp upped their price objective on shares of BeOne Medicines from $396.00 to $405.00 and gave the company a “market outperform” rating in a report on Thursday, August 6th. Finally, Nomura upgraded shares of BeOne Medicines to a “strong-buy” rating in a research report on Monday, July 27th. Three research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, BeOne Medicines currently has an average rating of “Buy” and an average target price of $402.14.

Institutional Investors Weigh In On BeOne Medicines

Several institutional investors have recently made changes to their positions in ONC. Renaissance Technologies LLC purchased a new position in BeOne Medicines during the 1st quarter valued at about $19,438,000. BNP Paribas Financial Markets lifted its holdings in shares of BeOne Medicines by 100.6% in the fourth quarter. BNP Paribas Financial Markets now owns 193,951 shares of the company’s stock worth $58,924,000 after buying an additional 97,244 shares in the last quarter. Rokos Capital Management LLP bought a new position in shares of BeOne Medicines in the first quarter valued at approximately $4,256,000. SEB Asset Management AB bought a new position in shares of BeOne Medicines in the first quarter valued at approximately $16,653,000. Finally, Generali Investments Management Co LLC purchased a new position in BeOne Medicines during the second quarter valued at approximately $2,280,000. Hedge funds and other institutional investors own 48.55% of the company’s stock.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.